ArticleJournal of cellular and molecular medicine2026
Early SOX9 Activation Primes Hippo-YAP/TAZ Rewiring During Glioblastoma Stemness Acquisition.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Glioblastoma progression is driven by stemness acquisition and cellular plasticity, yet the temporal and spatial organization of these processes remains incompletely defined. In this study, single-cell RNA sequencing, pseudotime reconstruction, spatial transcriptomics, and in vitro and in vivo functional assays were integrated to delineate the role of SOX9 during glioblastoma stemness acquisition. SOX9 expression peaked during the early astrocyte-to-malignant transition and declined after malignant states became stabilized. Along pseudotime, SOX9 was inversely associated with the upstream Hippo kinase module and showed phase-dependent coupling with YAP/TAZ-associated transcriptional programmes. Spatial analyses further revealed marked regional heterogeneity, with the strongest SOX9-malignant coupling observed in the perivascular niche. Functionally, SOX9 gain and loss produced reciprocal changes in glioblastoma cell proliferation, migration, invasion, apoptosis, and xenograft growth, while pharmacological modulation of Hippo signalling partially rescued the effects induced by SOX9 loss. Consistent pathway-level changes were also observed in YAP/TAZ expression and p-YAP/YAP and p-MOB1/MOB1 ratios, and xenograft histology showed SOX9-associated morphological and CD68-positive cell changes. These findings identify SOX9 as a temporally restricted regulator of glioblastoma stemness acquisition and support an early priming-late decoupling model of Hippo-YAP/TAZ rewiring, providing a rationale for stage-specific and niche-aware therapeutic targeting in glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.